NP-1031
NP-1031 is an oxytocin receptor modulator which is under development for the treatment of Prader–Willi syndrome.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
NP-1031 is an oxytocin receptor modulator which is under development for the treatment of Prader–Willi syndrome. Its route of administration has not been specified. The drug has been described as an "obesity therapy".
Deficient oxytocin system signaling may be present in Prader–Willi syndrome and may contribute to behavioral features such as hyperphagia and behavioral difficulties, although more research is needed in this area. NP-1031 is being developed by Novel Pharma in South Korea. As of March 2025, the drug is in the research stage of development.
The chemical structure of NP-1031, and whether it is a small molecule or a peptide, do not yet appear to have been disclosed. Our Pipeline - Novel Pharma
Text derived from https://en.wikipedia.org/w/index.php?oldid=1374092710 under CC BY-SA 4.0; modifications have been made.